Physician profile
Andrew Ip
NPI 1306102934
$169,000.29
in general payments reported to CMS, 2019-2025
18 companies · $21K in 2025
The $21K reported for 2025 was more than what 88% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.46 · 2021: $3,958 · 2022: $22K · 2023: $77K · 2024: $45K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Travel and Lodging: $44K · Consulting Fee: $29K · Honoraria: $5,200 · Food and Beverage: $3,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,520.30 |
| Travel and Lodging | $44,036.47 |
| Consulting Fee | $28,815.00 |
| Honoraria | $5,200.00 |
| Food and Beverage | $3,007.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $69,759.51 | 2020-2023 | Adcetris |
| Gilead Sciences, INC. | $35,349.50 | 2024-2025 | Yescarta |
| Genmab U.S., INC. | $29,734.94 | 2023-2024 | Epkinly |
| Pfizer INC. | $14,493.83 | 2022-2025 | |
| Abbvie INC. | $8,414.69 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $3,911.84 | 2021-2023 | Calquence |
| Kite Pharma, INC. | $2,400.82 | 2022-2025 | Yescarta |
| Tg Therapeutics, INC. | $1,665.00 | 2021 | |
| Secura Bio, INC. | $1,500.00 | 2022 | |
| Beigene USA, INC. | $1,306.52 | 2023 | |
| Janssen Biotech, INC. | $184.55 | 2021-2022 | |
| Genentech USA, INC. | $131.41 | 2022-2023 | Lunsumio |
| Celgene Corporation | $68.67 | 2024-2025 | Breyanzi |
| Pharmacyclics LLC, An Abbvie Company | $46.75 | 2021-2023 | Imbruvica, Epkinly |
| E.R. Squibb & Sons, L.L.C. | $17.27 | 2025 | Reblozyl |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.99 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Ip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.